We are live on ! Find out more
ROTUOC

Regents of the University of California Portfolio holdings

AUM $4.36B
1-Year Est. Return 33.89%
This Fund
S&P 500
This Quarter Est. Return
+273.42%
1 Year Est. Return
+33.89%
3 Year Est. Return
+86.09%
5 Year Est. Return
+63.96%
10 Year Est. Return
+870.04%
AUM
$190M
AUM Growth
+$137M
Cap. Flow
+$54.9M
Cap. Flow %
28.94%
Top 10 Hldgs %
91.14%
Holding
31
New
5
Increased
1
Reduced
5
Closed
2

Sector Composition

Rank Sector Weight
1 Healthcare 81.86%
2 Technology 6.45%
3 Consumer Staples 4.16%
4 Financials 2.71%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADP icon
26
Automatic Data Processing
ADP
$108B
$264K 0.14%
1,550
EB
27
DELISTED
Eventbrite
EB
$224K 0.12%
+11,127
New +$213K
UPWK icon
28
Upwork
UPWK
$1.05B
$155K 0.08%
14,516
-73,094
-83% -$921K
FINV
29
FinVolution Group
FINV
$1.07B
$135K 0.07%
50,952
-50,951
-50% -$135K
ARVN icon
30
Arvinas
ARVN
$583M
-20,833
Closed -$449K
VSM
31
DELISTED
Versum Materials, Inc.
VSM
-5,100
Closed -$270K

Similar funds

Regents of the University of California's Q4 2019 Portfolio in Review

As of Q4 2019, Regents of the University of California held 31 positions worth $190M, up 263% from $52.2M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Regents of the University of California deployed $54.9M of net new capital in Q4 2019, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Allogene Therapeutics: 2,350,930 shares worth $61.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 49% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $15.9M trimmed.

  • Regents of the University of California's largest Q4 2019 buy was Allogene Therapeutics: 2,350,930 shares worth $61.1M.
  • Regents of the University of California added most to Block Inc in Q4 2019, an estimated $1.76M increase.
  • Regents of the University of California's biggest Q4 2019 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $15.9M.
  • Regents of the University of California fully exited Arvinas in Q4 2019, selling an estimated $449K.
  • Regents of the University of California's ten largest holdings make up 91% of its $190M portfolio in Q4 2019.
  • Regents of the University of California opened 5 new positions and closed 2 in Q4 2019.
  • Regents of the University of California's portfolio value rose 263% quarter-over-quarter to $190M.

Based on Regents of the University of California's 13F filing for Q4 2019, filed 10 Feb 2020.